Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street (Private Bag 23), Hobart, Tas, 7000, Australia.
Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South, Australia.
BMC Ophthalmol. 2022 Feb 28;22(1):94. doi: 10.1186/s12886-022-02325-x.
To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus.
This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups.
The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05).
Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.
评估胰岛素治疗是否会影响抗血管内皮生长因子（抗-VEGF）注射治疗 2 型糖尿病性黄斑水肿（DME）的疗效。
这是一项回顾性多中心分析。比较了胰岛素组（N=137）和口服降糖药（OHA）组（N=61）在 12 个月时的最佳矫正视力（BCVA）、BCVA 变化、中心黄斑厚度（CMT）、CMT 变化和累积注射次数。
胰岛素组（p<0.001；p<0.001）和 OHA 组（p=0.199；p<0.001）的最终 BCVA 和 CMT 均有改善。两组在最终 BCVA（p=0.263）、BCVA 变化（p=0.184）、最终 CMT（p=0.741）、CMT 变化（p=0.458）和累积注射次数（p=0.594）方面无差异。当按基线视力（p>0.05）和基线 HbA1c（p>0.05）分层时，两组的结果相似。
胰岛素治疗不会改变 DME 患者抗-VEGF 治疗的疗效。
